HISTORY / BACKGROUND
Cell2Cure ApS is a clinical stage biotherapeutic company using allogeneic adipose tissue derived mesenchymal stromal cells for cellular therapies. It is a spinout company from the Cardiology Stem Cell Centre, Rigshospitalet, Copenhagen University Hospital, Denmark.
Cell2Cure has developed ‘off-the-shelf’ adipose tissue derived mesenchymal stromal cell (ASC) products in several clinically relevant formulations and from healthy donors. The ASC products are evaluated as new regenerative therapies in a wide range of advanced-stage diseases with involvement of inflammation and immunological activity, blood circulatory disturbance, fibrosis and scar development. The cell products have proven safety and promising efficacy in more than 300 patients with heart failure, left bundle branch block in the heart, reduced tear production in Sjögren’s syndrome, radiation-induced hyposalivation and xerostomia in previous head and neck cancer patients and in lung transplantation patients.
It is our vision to develop and produce therapeutic ASC products, that can be part of new effective regenerative and immunosuppressive therapies for patients with a range of chronic diseases in need of new treatment options.
The management team behind Cell2Cure has years of experience with management, research, and development of live cell-based pharmaceuticals. The team covers all relevant areas of expertise, including clinical development within several clinical disease indications, , cell biology, translational research, GMP production of advanced therapy medicinal products, quality, regulatory affairs, business development and company management.
Professor Jens Kastrup MD, DMSc, FESC
CEO and clinical director
Annette Ekblond M.Sc., Ph.D.
Director of R&D, GMP and regulatory affairs
Mandana Haack-Sørensen M.Sc., Ph.D.
Director of manufacturing
Martin Roland Jensen M.Sc. Ph.D.
SME Instrument grant
This project has received funding from the European Union’s SME Instrument, Horizon 2020 research and innovation programme under grant agreement No [H2020-SMEINST-868284_PRO-SCT]
Grand Solution Grant
Cell2Cure, as part of the consortium Clinical Stem cell Innovation and production Center, CSIC, receives funding from Innovation Fund Denmark.